Health systems need to heed a wide range of reimbursement problems that can trigger negative payments for high-cost oncology medications, including outdated billing codes, poorly coordinated prior authorizations and using generic billing codes for monoclonals when specific codes have been published, according to a new analysis of payment records at a major academic center.

Source link